Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 610-617

  Smith Jones, Peter M ^a   Vallabhajosula, Shankar ^a   Navarro, Vincent ^a   Bastidas, Diego ^a   Goldsmith, Stanley J ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

111In DOTA huJ591; 131I huJ591; Monoclonal antibody; Prostate specific membrane antigen; Tumor localization

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID IN 111; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBOXYPEPTIDASE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; INDIUM; MEMBRANE ANTIGEN; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; AUTORADIOGRAPHY; BLOOD; CONTROLLED STUDY; DRUG CLEARANCE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN DOMAIN; RADIOACTIVITY; RADIOIMMUNOTHERAPY; TIME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; EVALUATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; RADIOGRAPHY; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0038315416     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259-2269.
2. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-640.
3. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
4. Trover JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids Int J Cancer. 1995;62:552-558.
5. Israeli RS, Poweli CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
6. Wright GL, Grob BM, Haley C, et al. Up-regulation of prostate specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
7. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium Cancer Res. 1997;57:3629-3634.
8. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 1999;59: 3192-3198.
9. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate specific membrane antigen is produced in tumor-associated neovasculature Clin Cancer Res. 1999;5:2674-2681.
10. Dumas F, Gala JL, Berteau F, et al Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer. 1999;80:799-803.
11. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen-current and future utility. Semin Urol Oncol 1998;16:2-12.
12. 90Y-huJ591 MAb specific to PSMA radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor [abstract]. Eur J Nucl Med. 2000;8:951.
13. Holmes EH PSMA specific antibodies and their diagnostic and therapeutic use. Exp Opin Invest Drugs. 2001;10:511-519.
14. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927-936.
15. Troyer JK, Feng Q, Beckett ML, Wright GL Jr. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol. 1995;1:29-37.
16. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 1994;152:1490-1495.
17. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med. 1998;23:672-677.
18. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate specific membrane antigen. Cancer Res. 1998;58:4055-4060.
19. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res. 2000;60:5237-5243.
20. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
21. 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2:1289-1297.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1994;72:77-89.
23. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 1990;50:6423-6429.
24. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997:30:232-242.
25. Locin MF, Desreux JF, Merciny E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem. 1986;25:2646-2648.
26. Clarke ET, Martel AE. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tertaazamacrocycles Inorganica Chimica Acta. 1991;190:37-46.
27. Broan CJ, Cox JPL, Craig AS, et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazucyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radiotherapy - x-ray molecular structure of the indium and gallium complexes of 1,4,7- triazacyclononane-1,4,7-triacetic acid J Chem Soc Perkin Trans II 1991;2:87-99.
28. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997;38.1180-1185.
29. 90Y-labeled 1B4M-DTPA anti-tac monoclonal antibody distribution J Nucl Med. 1999;40: 268-276.
30. 131I-labeled CO17-iA in a human colorectal cancer model. Int J Cancer. 1998;76:738-748.
31. 177Lu-DOTA-J591 in nude mice bearing LNCaP tumors [abstract]. J Nucl Med. 2001;42(suppl): 151P-152P.